mineralystx.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $159.18MM
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone levels. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys is initially developing for the treatment of patients with uncontrolled hypertension. The company has plans for the continued research and development of lorundrostat in hypertension and other potential indications. Mineralys Therapeutics was founded in 2019, and is headquartered in Radnor, Pennsylvania.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
06/08/2022 | Series B | $118MM | $xx.xx | $267.43MM | RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysis Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments, Adams Street Partners | |
Price per Share
$xx.xx
Shares Outstanding
136,510,868
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
RA Capital Management, Andera Partners, RTW Investments, Rock Springs Capital, SR One Capital Management, Sectoral Asset Management, Ysis Capital, HealthCor Management, Boulder Ventures, Catalys Pacific, Samsara BioCapital, HBM Healthcare Investments, Adams Street Partners
|
||||||
04/06/2021 | Series A | $41.18MM | $xx.xx | $82.36MM | HBM Healhcare Investments, Samsara BioCapital, Catalys Pacific, Adams Street Partners | |
Price per Share
$xx.xx
Shares Outstanding
86,332,216
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
800.0%
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
2.5
Key Investors
HBM Healhcare Investments, Samsara BioCapital, Catalys Pacific, Adams Street Partners
|